Adaptimmune Therapeutics plc Stock News

- Outlined strategy to build integrated cell therapy company and the Company's “2-2-5-2” five-year core value drivers -

Immense potential, TCR therapy leader, but early stage. Science looks excellent with some proof of concept but risks, especially toxicity risks, abound.

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

- Data support confidence in SPEARHEAD-1 as a registrational trial -

- Data support continued development of ADP-A2M4CD8 -

Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients -

Oct 09, 2020 (CDN Newswire via Comtex) -- To gain insightful analysis and to have comprehensive understanding of the Spear Phishing Market and its commercial...

Keeping your floors clean is a real chore. But reliable robot vacuums like the 360 S9 can help out with that.

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

It might be of some concern to shareholders to see the Adaptimmune Therapeutics plc (NASDAQ:ADAP) share price down 14...